share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4：持股变动声明-高管 Kulkarni Samarth

美股SEC公告 ·  01/31 17:49

Moomoo AI 已提取核心信息

CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a stock transaction involving the sale of 50,000 common shares on January 29, 2024. The shares were sold at prices ranging from $60.5031 to $61.0998, resulting in a total market value of $3,025,572.69. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 187,377 common shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a stock transaction involving the sale of 50,000 common shares on January 29, 2024. The shares were sold at prices ranging from $60.5031 to $61.0998, resulting in a total market value of $3,025,572.69. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 187,377 common shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics AG的首席执行官萨玛斯·库尔卡尼于2024年1月29日完成了一项涉及出售50,000股普通股的股票交易。这些股票的出售价格从60.5031美元到61.0998美元不等，总市值为3,025,572.69美元。在此次出售之前，库尔卡尼行使了期权，以每股19.12美元的价格收购了相同数量的股票。交易完成后，库尔卡尼直接持有187,377股普通股。此外，库尔卡尼通过库尔卡尼2023年GRAT拥有20万股股票的间接实益所有权。
CRISPR Therapeutics AG的首席执行官萨玛斯·库尔卡尼于2024年1月29日完成了一项涉及出售50,000股普通股的股票交易。这些股票的出售价格从60.5031美元到61.0998美元不等，总市值为3,025,572.69美元。在此次出售之前，库尔卡尼行使了期权，以每股19.12美元的价格收购了相同数量的股票。交易完成后，库尔卡尼直接持有187,377股普通股。此外，库尔卡尼通过库尔卡尼2023年GRAT拥有20万股股票的间接实益所有权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间